OrbiMed is a leading global healthcare investment firm that invests across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. Founded in 1989, OrbiMed seeks to invest globally in world-class healthcare companies to help drive innovation, address unmet medical needs, and improve patient outcomes. The firm provides tailored financing solutions and extensive global team resources to help build world-class healthcare companies. The firm focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. OrbiMed is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Hezliya, and other key global markets.
ABOUT ORBIMED
OrbiMed is a global healthcare investment firm that provides tailored financing solutions and global team resources to help build world-class healthcare companies.
OrbiMed's structure combines the focus of specialists dedicated to specific market sectors with the synergies of a broad investment team spanning both public equity and private markets around the world.
The firm has evolved into one of the largest dedicated healthcare investment firms worldwide, with approximately $18 billion in assets under management as of March 2024.
Notable investments included $400 million in debt financing to Caris Life Sciences Inc., $200 million in Series C funding to ADARx Pharmaceuticals Inc., and $200 million in Series B funding to Upstream Biosciences Inc.
ORBIMED STRATEGIES
OrbiMed's private equity strategy helps build portfolio companies into market leaders. The firm invests globally including North America, Asia, and Europe.
Private Credit/Royalty.
OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital, providing valuable financing solutions to owners of intellectual property.
OrbiMed manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. The firm invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide.